Treatment of dilated cardiomyopathy with Bicom bioresonance

Dr. Esra Kirsever, Istanbul, Türkei

Dear participants,

acceptance of our study in this year’s BICOM® congress made me very happy as physician, and practitioner of BICOM® bioresonance therapy for 2 years. I am working in my private clinic in my country as a specialist in obstetrics and gynecology. I have met BICOM® bioresonance therapy (BRT) method on the occasion of my mother’s health problems. My mother was receiving immunosuppressive therapy for autoimmune hemolytic anemia for eight years because the cause of her disease and specific treatment was not known in traditional medicine. She was diagnosed with multiple myeloma in November 2011 as one of the possible consequences of immunosuppressive therapy she was receiving and her life expectancy was projected 1 year. Minimum of four cycles of chemotherapy (CT) and spine surgery were planned. Complete remission was achieved in 2 months after two cycles of chemotherapy. I administered BRT during the same period. So, she did not need surgery. And my mother has been healthy since 1 year.

I shared the miraculous results of this treatment with my doctor friends, and I administered BRT to them and their relatives from time to time. We had successful results every time, especially for problems that had failed with conventional medical treatments. Prof. Dr. Osman Karakaya, a cardiologist, who is one of these friends of mine, offered to perform a joint research on the effectiveness of BRT for treatment of patients with cardiomyopathy that remained untreatable. I accepted that offer gladly and eagerly.

We launched our research in August 2012 together with Assistant Dr. Ismail Ungan, who followed-up patients in clinical practice for cardiological aspects, Assistant Dr. Alper Vural, who accompanied the treatments as the cardiologic follow-up, and Dr. Zeynep Karabey who supported us all the time with her knowledge and experience on BRT.


Dilated cardiomyopathy (DCM) is characterized by dilation and impaired contraction of one or both ventricles. Affected patients have impaired systolic function and may or may not develop overt heart failure (HF). The presenting manifestations can include atrial and/or ventricular arrhythmias, and sudden death can occur at any stage of the disease.

Dilated cardiomyopathy is currently responsible for approximately 10,000 deaths and 46,000 hospitalizations each year in the United States. Furthermore, idiopathic DCM is the primary indication for cardiac transplantation.

A diagnosis of DCM requires evidence of dilation and impaired contraction of the left ventricle or both ventricles (e.g. left ventricular Ejection Fraction (EF) < 40 percent or fractional shortening less than 25 percent). The disease is considered idiopathic if primary and secondary causes of heart disease (e.g. myocarditis and coronary artery disease) are excluded by evaluation including history and physical examination, laboratory testing, coronary angiography (to exclude >50 percent obstruction of one or more coronary arteries), echocardiography and endomyocardial biopsy when indicated.

Table 1: NYHA Classification – The Stages of Heart Failure

NYHA Classification – The Stages of Heart Failure

Most patients present DCM between the age of 20 and 60 but DCM can occur in children and older adults. Symptoms of heart failure: fatigue and weakness, progressive dispose with exertion, impaired exercise capacity, orthopnea, paroxysmal nocturnal dyspnea and peripheral edema are most common. Other presentations include the incidental detection of asymptomatic cardiomegaly and symptoms related to coexisting arrhythmia, conduction disturbance, thromboembolic complications or sudden death.

The clinical course is largely unpredictable in the individual patient and may depend in part upon the cause of the heart disease. There are also disease-independent predictors of survival, the most important of which are New York Heart Association functional class (Table 1), left ventricular EF, and maximal oxygen consumption (peak VO2) (1). Another parameter which is accepted as a good biochemical marker following a myocardial dysfunction is NTproBNP (2).

These prognostic determinants assume that the cause of the myocardial dysfunction cannot be treated.

Dilated cardiomyopathy can be caused by a variety of disorders (Table 2). These conditions will be briefly reviewed here. Many are discussed in detail elsewhere. In many cases, however, no etiology can be found and the cardiomyopathy is deemed idiopathic.

The relative frequency of the different causes in patients with initially unexplained cardiomyopathy was assessed in a review of 1,230 patients (3).

– Idiopathic 50 percent
– Myocarditis 9 percent
– Ischemic heart disease 7 percent
– Infiltrative disease 5 percent
– Peripartum cardiomyopathy 4 percent
– Hypertension 4 percent
– HIV infection 4 percent
– Connective tissue disease 3 percent
– Substance abuse 3 percent
– Doxorubicin 1 percent
– Other 10 percent

The causes of cardiomyopathy have sometimes been divided into reversible and irreversible disorders. However, this distinction is somewhat arbitrary since many of these conditions can be either reversible or nonreversible.

Ischemic cardiomyopathy

Most patients with ischemic cardiomyopathy have known coronary artery disease. However, an occult disease is a not uncommon cause of DCM, accounting for as many as 7% of otherwise unexplained cases.

Table 2: Major causes of dilated cardiomyopathy

NYHA Classification – The Stages of Heart Failure

Stress-induced cardiomyopathy

An uncommon but increasingly reported cause of an acute, usually ST-elevation coronary syndrome occurring in the absence of critical coronary artery disease is stress-induced cardiomyopathy, also called transient left ventricular apical ballooning, &ldquo;takotsubo cardiomyopathy&rdquo;, and broken heart syndrome. This is a temporary heart condition brought on by stressful situations, such as the death of a loved one. The characteristic finding of apical ballooning is seen on left ventriculography or echocardiography.

Infect-induced cardiomyopathy

A variety of infectious organisms may lead to myocarditis and DCM (Table 3).

Table 3: Infect-induced cardiomyopathy

Infect-induced cardiomyopathy

Viral cardiomyopathy

Viruses known to involve the myocardium include parvovirus B19, human herpes virus 6, Coxsackie viruses, influenza virus, adenovirus, ECHO virus, cytomegalovirus, and human immunodeficiency virus (HIV).

They cause myocyte injury that may ensue via direct cytotoxicity and/or adverse autoimmune response. The initial response, however, limits the degree of viremia early during infections and protects against myocarditis.

Chagas disease
Chagas disease, which is a protozoan infection due to Trypanosoma cruzi, is the leading cause of DCM in Central and South America.

Lyme disease
Lyme disease which is a bacterial infection due to Borrelia, is the leading cause in the northern latitudes.

A number of genes linked to DCM.

Inherited syndromes
Dilated cardiomyopathy can be a common and important component of a number of inherited disorders, including a number of neuromuscular diseases (e.g. muscular dystrophies, and myotonic dystrophy), hereditary hemochromatosis, and the hereditary sideroblastic anemias and thalassaemia.

Toxic cardiomyopathy
DCM can be a direct result of toxic exposure from a variety of agents, most notably alcohol, cocaine, medications, particularly chemotherapeutic drugs, and radiation.

Alcohol: Toxic to cardiac myocytes via oxygen free radical damage and defects in cardiac protein synthesis.

Cocaine: Direct toxic effect (the cocaineinduced hyperadrenergic state, and infectious cardiomyopathy).

Medications: Some drugs that are used in antibiotic therapy and chemotherapy may cause DCM.

Toxins: This condition can also be caused by exposure to some metals and toxic compounds such as lead, mercury, cobalt, copper, iron, arsenic, antimony gold, chromium.

Peripartum cardiomyopathy
Tachycardia-mediated cardiomyopathy
End-stage renal disease

Systemic lupus erythematosus

Celiac disease: Two reports from Italy suggest that celiac disease, which is often clinically unsuspected, accounts for as many as 5% of patients with autoimmune myocarditis or idiopathic DCM. In one report of nine such patients, none had classic gastrointestinal symptoms of celiac disease (recurrent abdominal pain, diarrhea, and weight loss), but all had iron deficiency anemia refractory to iron replacement. Cardiac function improved following a gluten-free diet with or without immunosuppressive therapy.

Endocrine dysfunction: Thyroid dysfunction, excess sympathetic activity in pheochromocytoma, and rarely Cushing’s syndrome and growth hormone (GH) excess or deficiency can cause cardiac dysfunction.

Nutritional deficiencies: Deficiencies in thiamine, selenium, and L-carnitine have been reported to produce heart failure. Replacement therapy causes improvement in cardiac function.

Treatment of DCM in cardiology

Medical treatment

– ACE inhibitors
– Angiotensin II receptor blockers
– Beta blockers
– Digitalis
– Diuretics
– Anticoagulants


Implantable devices to treat DCM:

– Biventricular pacemakers
– Implantable cardioverter defibrillators
– Heart pump

Heart transplantation
Patient may be candidate for a heart transplant if medication and other treatments are no longer effective. Guidelines for pharmacological and device therapies in heart failure make little references to etiology specific management. (1)

Research details
• In our research, 4 male patients diagnosed with ‘‘Non-Ischemic Dilated Cardiomyopathy’’ were informed about bioresonance therapy project and their consents were obtained. Routine cardiological examinations, biochemical, hematological parameters, electrocardiography, echocardiography examinations of the patients were performed by the cardiology clinic. Their blood samples were taken for levels of NT-proBNP, accepted as a good marker in myocardial dysfunction follow-up.
• First, a detailed medical history was taken from the patients planned for bioresonance therapy in my clinic.
• Patients assessed their complaints (13 variables) according to a symptomatology scoring from 1 to 10 (Table 4).
• The functional classification of New York Heart Association was taken as a basis for the assessment of clinical functional capacity of the patients.
• BMI values were calculated by measuring the patients’ heights, weights.
• Hamer focus examination was performed kinesiologically (Hamer Focus = conflict energy focus on the brain with specific relation to the organs).
• Their EAP (elektro-acupuncture) tests were performed.
• Their blood samples were taken. These blood samples were tested in basic test (elimination organs, scars, other interferences) and CTT (Combined Test Technique) panels prior to the start of the therapy. BRT treatment plan was prepared according to the test results (Table 5).

Table 4: Complaints of patients according to the symptomatology scoring

Complaints of patients according to the symptomatology scoringBefore and after therapy mean score of patients

Blood sample resultsTherapy procedure of bioresonance

First basic systematic bioresonance procedure (Table 6), completed by specific procedures.

Table 6: Basic systematic treatment procedure

Basic systematic treatment procedure

Table 7: Procedure of specific therapies

Procedure of specific therapies

Additional therapies
In addition to specific programs for heart failure, the following treatment programs were administered:

Hamer focus treatment programs (999, 998)
Allergy, stress blockage (10027)
Shock therapy (10147)
Hormone programs (10070, 10072)
Adrenaline-regulation (10006)
Cell stimulation (10193)

Nutritional point therapy was performed according to the Sissi Karz protocol (for point location see graphic in the Appendix).

Those suitable were selected and with heart programs administered via channel 2.

Individual Bach flower remedies to combat emotional stress and ampoules from the CTT Test Kit of the 5 Functional Circuits were also used in BICOM BICOM optima® channel 2 to support the organ systems.

The basis for the evaluation of the research results were five parameters:

1. Symptomatology scoring (Table 4)
2. Functional scoring according to NYHA Classification (Table 1)
3. Body Mass Index (BMI)
4. Measurement of EF echocardiographically
5. Determination of NT-proBNP in the blood


Case 1
S.S. 48 years old, taxi driver, married, 3 children

3 children had died (1-month, 8 months, 8 years old). The child who died when he was 8 years old, had congenital heart disease, tetralogy of Fallot. The family had a very intensive treatment and operation period. He lost his mother and father 4 days apart.

The diagnosis of non-ischemic DCM was established incidentally during an operation he had 2 months ago. The patient underwent BRT of 20 sessions. The treatment schedule was as follows.

– Geopathy/E-smog treatment
– Wheat allergy
– Blockage: scar navel and operation scars, cervical blockage, spinal blockage
– Pathogenic infection: Coxsackie B6, Cytomegalovirus, Epstein
-Barr virus, Candida
– Heavy metal accumulation, cadmium
– Hamer focus, bilateral temporal
– Chackra therapy, 1st Level, 1st Chakra
– Selenium, Thiamin and Calcium were administered orthomolecularly
– Meridian therapies based on EAP: heart, lung / triple warmer
– Programs that were suitable from among cardiomyopathy treatment programs were selected with the help of the biotensor and applied.

Table 8: Clinical results of S.S: before and after therapy

Clinical results of S.S: before and after therapy

Case 2
S.A., 44 years old, welding master, married, 3 children

He has a healthy, trouble-free family structure. He lost his mother and father 40 days apart. He was diagnosed with thyrotoxicosis 6 years ago. He had been treated with radioactive iodine. He was diagnosed with DCM 4 years ago. So far, he underwent 16 bioresonance sessions. The treatment schedule was as follows.

– Geopathy/E-Smog treatment
– Wheat, milk, yeast allergy
– Blockage treatments: scar, chin (very significant), spinal, sacral
– Pathogenic infection: Coxsackie B6, Cytomegalosvirs, Epstein
-Barr virus, Herpes simplex virus, Candida, haemolytic streptococcus
– Heavy metal accumulation, cadmium
– Hamer focus
– Chakra therapy, 2nd Level, 2nd Chakra
– Meridian therapies based on EAP: liver, spleen, heart
– Programs that were suitable from among specific treatment programs were selected with the help of the biotensor and applied

Table 9: Clinical results of S.A: before and after therapy

Clinical results of S.A: before and after therapy

Case 3
S.Y., 56 years old, butcher, married, 3 children

One of his daughters is mentally disabled due to a birth trauma. His wife operated for breast cancer receiving radiotherapy and chemotherapy.

The diagnosis of DCM was established 4 years ago. A device treatment in a private clinic was planned. The patient underwent 19 bioresonance sessions. The treatment schedule was as follows.

– Geopathy/E-Smog
– Wheat allergy
– Blockage treatments: scar blockage, laterality (prominent), immune system
– Pathogen: Coxsackie B6, Cytomegalovirus, Epstein-Barr virus, Candida, haemolytic streptococcus
– Heavy metal contamination was not detected
– Hamer focus, left frontal
– Chakra: 4th chakra
– Meridian based on EAP: metabolism, TW, lung, liver, connective tissue, bladder, spleen
– The miracle meridian therapy was applied to the patient due to the large number of meridian therapy needs.
– Selenium, Vitamin B6, Thiamine were administered orthomolecularly
– Programs that were suitable from among specific treatment scheme were selected with the help of biotensor and applied.

Table 10: Clinical results of S.Y: before and after therapy

Clinical results of S.Y: before and after therapy

Case 4
A.U., 46 years old, dealer of electronic equipment and air conditioner, married, 2 children

His son was diagnosed with optic glioma 10 years ago and eye enucleation was proposed. He was treated with radiotherapy.

A.U. had had sudden tachycardia complaints triggered by coffee 8 years ago and was hospitalized with a diagnosis of ventricular tachycardia. The diagnosis of DCM was established 8 years ago. The patient underwent 18 bioresonance sessions. The treatment schedule was as follows.

– Geopathy/E-Smog (E-Smog was very prominent)
– Wheat allergy
– Blockage treatments: chin, scar, spinal, immune system
– Pathogens: Coxsakie B6, Candida
– Heavy metal contamination, mercury
– Hamer focus: bilateral temporal
– Chakra: 4th Chakra
– Selenium, B6, thiamin were administered orthomolecularly.
– Meridian based on EAP: TW, heart, bladder
– Programs that were suitable from among specific treatment programs were tested with the help of the biotensor and applied.

Table 11: Clinical results of A.U.: before and after therapy

Clinical results of A.U.: before and after therapy


1. Our research is in line with the literature about DCM aetiology.

• A history of a sudden death or serious illness of a family member prior to the illness were common in each of the 4 patients as a common anamnesis feature of the patients.
• Wheat allergy supporting the association of Celiac DCM (4, 5) was found to be the common allergen in the patients.
• Coxsackie B6 virus and Candiasis were found to be the common pathogens in terms of pathogenic etiology and were treated.
• Again, in line with the literature, Selenium, Vitamin B6, L-Carnitine, Thiamine and Ca deficiencies were tested and determined according to the Sissi Karz protocol.

2. No clinical deterioration was observed in any of the patients during the treatment process. They did not require hospitalization. The patients well adapted to the treatment. The lack of need for hospitalization of patients is a good prognostic factor in the practice of cardiology.

3. At the end of the 20 bioresonance therapy sessions applied to the patients:

• An improvement of an averagely rate of 80.4% was observed in the symptomatology scoring.
• An improvement of two stages was observed according to the NYHA Classification.
• BMI decreased by 6.37%.
• Ejection Fraction did not change in two patients in the echocardiographic evaluation. It returned to normal in one of the patients. Although it returned to normal in one of the patients at session12 in the real-time echo, a decrease at week 20 was observed in echo in the patient who continued smoking.
• A significant and clinically compatible decrease was observed in all of the patients in the NT-proBNP value accepted as a quantitative good marker in myocardial contractility follow-up.

Our research is currently at the 20th session stage and continues.

In this study are taking part:

Doz. Dr. Alper Vural
Doz. Dr. Ismail Ungan
Prof. Dr. Osman Karakaya
Prof. Dr. Nurhan Đnce


1. Dilated Cardiomyopathy. DS01029/DSECTION=treatments-and-drugs.

2. Nasser N, Perles Z, Rein AJ, Nir A. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr. Cardiol 2006:27:87-90.

3. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000: 342:1077.

4. Curione M, Barbato M, De Biase L, et al. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. Lancet 1999: 354:222.

5. Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002: 105:2611.

6. BICOM BICOM optima® Program Manual, Sissi Karz – Vitamin and Nutrition Points, Regumed GmbH, 2009




pdf download button